Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / DALIM TISSEN Co., Ltd.

Clinicaltrial registered16 Nov 2026

DALIM TISSEN Co., Ltd.

16 Nov 2026: Trial registered · Safety and Efficacy of BioSeal as a Surgical Adhesive in Cardiovascular Surgery. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
16 Nov 2026
Title
Safety and Efficacy of BioSeal as a Surgical Adhesive in Cardiovascular Surgery
Conditions
Cardiovascular Surgery, Vascular Anastomosis Surgery
Phase
Not applicable
Study Type
Interventional
Status
Recruiting
Countries
South Korea
Country
South Korea
Reference
NCT07940296
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at DALIM TISSEN Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.